DexCom Operating Cash Flow increased by 78.8% to $525.60M in Q1 2026 compared to the prior quarter. Year-over-year, this metric grew by 186.0%, from $183.80M to $525.60M. Over 4 years (FY 2021 to FY 2025), Operating Cash Flow shows an upward trend with a 34.3% CAGR. This is a positive signal — higher values indicate stronger performance for this metric.
An increase indicates strong operational efficiency and cash generation, while a decrease may signal operational challenges or issues with working capital management.
This metric represents the total cash generated or consumed by a company's core business operations during a specific pe...
Standard across all industries; peers in the medical device and diagnostics sector typically maintain high conversion ratios of net income to operating cash flow.
net_cash_from_operating| Q2 '21 | Q3 '21 | Q4 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $61.60M | $247.30M | $105.80M | $71.00M | $172.80M | $293.20M | $132.50M | $155.40M | $190.30M | $269.20M | $133.60M | $209.20M | $279.40M | $199.50M | $301.40M | $183.80M | $303.00M | $659.90M | $294.00M | $525.60M |
| QoQ Change | — | +301.5% | -57.2% | -32.9% | +143.4% | +69.7% | -54.8% | +17.3% | +22.5% | +41.5% | -50.4% | +56.6% | +33.6% | -28.6% | +51.1% | -39.0% | +64.9% | +117.8% | -55.4% | +78.8% |
| YoY Change | — | — | — | — | +180.5% | +18.6% | +25.2% | +118.9% | +10.1% | -8.2% | +0.8% | +34.6% | +46.8% | -25.9% | +125.6% | -12.1% | +8.4% | +230.8% | -2.5% | +186.0% |